Deep Knowledge Ventures Investor

Deep Knowledge Ventures is a Hong Kong based investment fund with teams in London, Geneva, and San Francisco. The fund primarily invests in DeepTech, AI, and advanced biomedicine. In 2014, DKV announced the use of VITAL (Validating Investment Tool for Advancing Life Sciences) -- a machine intelligence that analyses financial and scientific data to better inform investment decisions made by partners and the board of directors. In 2015, Deep Knowledge Ventures incorporated a subsidiary investment fund Deep Knowledge Life Sciences (DKLS) is a London-based venture fund focused on disruptive biopharmaceutical, medical device, and healthcare companies. In partnership with scientists at the Universities of Oxford and Cambridge, they aim to help solve the major global challenges related to demographic aging, the rise of non-communicable disease, and the integration of AI with an exponentially expanding ocean of bioinformatic data. They strategically invest in mission-driven companies and support founders who will bridge the unaddressed translational gap between basic biological research and real-world healthcare products that extend healthy lifespan. DKV aims to rethink the venture capital model and is involved with the development of blockchain technology (digital economy and AI) through its upcoming Digital Capital Fund, which focuses on fintech, legaltech, and govtech.

Invests into
Technology: Intelligent Data Analysis
Industry: Healthcare
Headquarters: Hong Kong
Founded Date: 2014
Employees Number: 11-50
Funding Status: N/A
Investor Type: Venture Capital
Investment Stage: Early Stage Venture, Grant, Private Equity, Secondary Market, Seed
Number Of Exits: N/A

Visit Website
Register and Claim Ownership